Olanzapine appears haematologically safe in patients who developed blood dyscrasia on clozapine and risperidone.
We report a 2-year experience with olanzapine treatment (20 mg daily) in a 65-year-old male patient with treatment-resistant paranoid schizophrenia, who had previously developed leucopenia and neutropenia first on clozapine and, subsequently, also on risperidone. Olanzapine seems to be safe in this patient, since no major decreases of haematological parameters were observed. The only exception was a brief decrease of leucocyte and neutrophil (but not erythrocyte or platelet) counts during influenza-like viral infection. However, the control of psychotic symptoms on olanzapine is not as good as on clozapine.
Dernovsek
M Z
MZ
University Psychiatric Hospital, Ljubljana-Polje, Slovenia. rok.tavcar@mf.uni-lj.si
Tavcar
R
R
D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines; D003024:Clozapine / Q000009:adverse effects* / Q000627:therapeutic use; D016903:Drug Monitoring; D006801:Humans; D007970:Leukopenia / Q000097:blood / Q000139:chemically induced*; D008297:Male; D009503:Neutropenia / Q000097:blood / Q000139:chemically induced*; D000077152:Olanzapine; D010890:Pirenzepine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012307:Risk Factors; D018967:Risperidone / Q000009:adverse effects* / Q000627:therapeutic use; D012563:Schizophrenia, Paranoid / Q000097:blood* / Q000188:drug therapy*
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D003024:Clozapine; D018967:Risperidone; D000077152:Olanzapine